By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cytheris SA 

Technopolis
175, rue Jean-Jacques Rousseau
Issy-les-Moulineaux    92130  France
Phone: 33-0-1-5888-3800 Fax: 33-0-1-4644-4446


SEARCH JOBS








Company News
Cytheris SA Announces U.S. Orphan Drug Designation for CYT107 for the Treatment of Progressive Multifocal Leucoencephalopathy (PML) 10/24/2012 10:19:46 AM
Cytheris SA Announces Publication in Blood Demonstrating CYT107 Reverses Lymphopenia and Increases Virus-Specific Immunity Post Stem Cell Transplantation 10/9/2012 12:03:48 PM
Cytheris SA Announces CYT107 Orphan Drug Designation in Europe for the Treatment of Progressive Multifocal Leucoencephalopathy (PML) 7/10/2012 9:16:33 AM
Cytheris SA Appoints Damian Marron as Chief Executive Officer 6/12/2012 10:56:54 AM
Cytheris SA Announces Results of Phase II Study Indicating That Recombinant Interleukin-7 (CYT107) Expands CD4 T-Cells in Gut Mucosa of Chronically HIV Infected Immunological Non-Responder Patients 3/8/2012 11:55:38 AM
Cytheris SA Announces Interim Results from ECLIPSE 2 Hepatitis C Multicenter Study of IL-7 in Chronically Infected Genotype 1 and 4 Nonresponders to Standard of Care (SOC) 11/8/2011 10:40:45 AM
Cytheris SA Announces Interim Results from ECLIPSE II Hepatitis C Multicenter Study of IL-7 in Chronically Infected Genotype One and Four Nonresponders to Standard of Care (SOC) 11/8/2011 10:13:16 AM
Cytheris SA to Present Interim Data from ECLIPSE 2 Hepatitis C Multicenter Study at AASLD Annual Meeting 10/26/2011 9:29:49 AM
Cytheris SA to Present Interim Data from ECLIPSE 2 Hepatitis C Multicenter Study at AASLD Annual Meeting 10/26/2011 8:43:06 AM
Cytheris SA and Cancer Immunotherapy Trials Network (CITN) Announce Selection of Recombinant Interleukin-7 (CYT107) for Initial Studies at Member Institutions 5/17/2011 9:35:20 AM
12345
//-->